相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel et al.
BLOOD (2010)
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
Benedetto Bruno et al.
BLOOD (2009)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta et al.
BLOOD (2009)
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease
Asha B. Pillai et al.
BLOOD (2009)
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Holbrook E. Kohrt et al.
BLOOD (2009)
Reduced-intensity allogeneic transplantation for myeloma: reality bites
A. Keith Stewart
BLOOD (2009)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Antje Hoering et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
G. Cook et al.
BONE MARROW TRANSPLANTATION (2009)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
Andrew Spencer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells
M. C. Minnema et al.
LEUKEMIA (2009)
Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Muzaffar H. Qazilbash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
Maurizio Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Advances in therapy of multiple myeloma
Joan Blade et al.
CURRENT OPINION IN ONCOLOGY (2008)
Stem-cell transplantation for multiple myeloma in the era of novel drugs
William Bensinger
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
Ulf-Henrik Mellqvist et al.
CANCER (2008)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M. Lokhorst et al.
HAEMATOLOGICA (2007)
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with Busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients
Enric Carreras et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Relationship between depth of response and outcome in multiple myeloma
David Dingli et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma
Gosta Gahrton et al.
HAEMATOLOGICA (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Laura Rosinol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Serum M-spike and transplant outcome in patients with multiple myeloma
David Dingli et al.
CANCER SCIENCE (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
John Koreth et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo
Ying Liu et al.
BLOOD (2006)
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The paradox of response and survival in cancer therapeutics
CA Huff et al.
BLOOD (2006)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe
J Fermand et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
J Bladé et al.
BLOOD (2005)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
R Bellucci et al.
BLOOD (2004)
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
R Alexanian et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
S Kumar et al.
BONE MARROW TRANSPLANTATION (2004)
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BLOOD (2004)
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
E Nadal et al.
BONE MARROW TRANSPLANTATION (2004)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
E Alyea et al.
BONE MARROW TRANSPLANTATION (2003)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini et al.
BLOOD (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM
HM Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning
H Einsele et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation
JA Pérez-Simón et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity
KS Peggs et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
CK Lee et al.
EXPERIMENTAL HEMATOLOGY (2003)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
N Kröger et al.
BLOOD (2002)
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
S Singhal et al.
BONE MARROW TRANSPLANTATION (2002)
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
S Giralt et al.
BONE MARROW TRANSPLANTATION (2002)
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
N Kröger et al.
BLOOD (2002)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
R Alexanian et al.
BONE MARROW TRANSPLANTATION (2001)
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
A Shimoni et al.
BONE MARROW TRANSPLANTATION (2001)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Donor leukocyte infusions for multiple myeloma
M Salama et al.
BONE MARROW TRANSPLANTATION (2000)
High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission.: Results of a non-randomized study from a single institution
J Bladé et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
